P/E ratio for Paratek Pharmaceuticals (PRTK)
P/E ratio as of May 2024 (TTM): -2.03
According to Paratek Pharmaceuticals 's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -2.02727. At the end of 2022 the company had a P/E ratio of -1.58.
P/E ratio history for Paratek Pharmaceuticals from 2009 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | -1.58 | -56.94% |
| 2021 | -3.68 | 28.75% |
| 2020 | -2.86 | 178.75% |
| 2019 | -1.03 | -28.64% |
| 2018 | -1.44 | -73.11% |
| 2017 | -5.34 | 95.34% |
| 2016 | -2.74 | -39.01% |
| 2015 | -4.48 | 10.48% |
| 2014 | -4.06 | 76.39% |
| 2013 | -2.30 | -60.7% |
| 2012 | -5.86 | -78.31% |
| 2011 | -27.0 | 151.76% |
| 2010 | -10.7 | 202.81% |
| 2009 | -3.54 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Ultragenyx RARE | -4.22 | 108.10% | 🇺🇸 USA |
 Spectrum Pharmaceuticals
SPPI | -2.86 | 41.13% | 🇺🇸 USA |
 Agenus
AGEN | -14.7 | 626.56% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.